Company performance
Add to research
Current Price
as of Mar 21, 2025$5.81
P/E Ratio
N/A
Market Cap
$447.45M
Description
Add to research
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Metrics
Add to research
Overview
- HQGaithersburg, MD
- SectorHealth Technology
- IndustryBiotechnology
- TickerALT
- Price$5.81+0.52%
Trading Information
- Market cap$447.45M
- Float98.96%
- Average Daily Volume (1m)3,305,461
- Average Daily Volume (3m)2,536,011
- EPS-$1.34
Company
- Revenue$0.02M
- Rev growth (1yr)-95.31%
- Net income-$95.06M
- Gross margin-1,090.00%
- EBITDA margin-514,670.00%
- EBITDA-$102.93M
- EV$381.68M
- EV/Revenue19,084.13
- P/EN/A
- P/S20,626.49
- P/B3.40
- Debt/Equity1.36
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset